NEVRO CORP. (NYSE:NVRO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
Entry into a Material Definitive Agreement. |
On December 19, 2016, Nevro Corp. (the Company) entered into a
First Amendment to Lease (the Lease Amendment) with Westport
Office Park, LLC (the Landlord) effective as of December 9, 2016,
amending the Lease Agreement dated as of March 5, 2015 (the
Original Lease) between the Company and the Landlord. Under the
Original Lease, the Company leases approximately 50,470 square
feet of office space located at 1800 Bridge Parkway, Redwood
City, California 94065 (the Original Premises). to the Lease
Amendment, the Company will lease an additional approximately
49,980 square feet of office space adjacent to the Original
Premises at 1600 Bridge Parkway, Redwood City, California 94065
(the Expansion Premises, and together with the Original Premises,
the Premises) for expansion of the Companys principal executive
offices.
The lease for the Expansion Premises commences on the earlier of
(i) the date the Company commences business operations in the
Expansion Premises, or (ii) the date upon which the Landlord
substantially completes certain improvements to, and permitting
for, the Expansion Premises (the Commencement Date). The lease
for the Expansion Premises terminates on the last day of the
calendar month following the date that is 84 months after the
Commencement Date and amends the lease term for the Original
Premises to terminate on the same date (the Lease Term). The
Company has an option to extend the Lease Term for an additional
five years (the Option Term), subject to certain conditions, upon
written notice to the Landlord.
The Lease Amendment provides for annual base rent for the
Expansion Premises of approximately $1.2 million in the first
year of the Lease Term, which increases on a yearly basis up to
approximately $2.9 million for the final year of the Lease Term
and annual base rent during the Option Term to be calculated
based on a ratable portion fair market rental value as described
in the Lease. The Lease Amendment also provides for certain
limited rent abatements in the first 15 months of the Lease Term.
The Company will also be obligated to pay to the Landlord for
certain costs, taxes and operating expenses related with the
Lease and the Premises, subject to certain exclusions.
The Company will be entitled to a one-time improvement allowance
of approximately $2.2 million for costs related to the design and
construction of Company improvements that are permanently affixed
to the Expansion Premises.
The foregoing description of the material terms of the Lease
Amendment is qualified in its entirety by the actual Lease
Amendment, which the Company intends to file as an exhibit to the
Companys Annual Report on Form 10-K for the year ended December
31, 2016.
Item 2.03. |
Creation of a Direct Financial Obligation or an |
(a) |
Creation of a Direct Financial Obligation. |
The information set forth under Item 1.01 of this Current Report
on Form 8-K with respect to the Lease is incorporated herein by
reference.
About NEVRO CORP. (NYSE:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. NEVRO CORP. (NYSE:NVRO) Recent Trading Information
NEVRO CORP. (NYSE:NVRO) closed its last trading session down -2.53 at 71.47 with 575,221 shares trading hands.